Literature DB >> 30682424

Intriguing relationship between antihypertensive therapy and cancer.

Marijana Tadic1, Cesare Cuspidi2, Evgeny Belyavskiy3, Guido Grassi4.   

Abstract

Arterial hypertension is the most frequent cardiovascular risk factor in the cancer patients. Anti-cancer therapy very often induces arterial hypertension and the treatment with antihypertensive medications is inevitable. Additionally, anti-cancer therapy frequently induces cardiotoxicity that has been treated or even could be prevented by use of antihypertensive medications - primarily angiotensin converting enzyme inhibitors and beta-blockers. The association between antihypertensive drugs and cancer is matter of large debate in the last several years because of the conflicting results from available studies ranging from adverse to beneficial effect of various antihypertensive classes. The mechanisms of the relationship between antihypertensives and cancer are still in domain of hypothesis. Some studies described the association between different antihypertensive groups and malignancies. There are investigations that denied negative effects of antihypertensive medications on cancer occurrence, recurrence, cancer-related complications and mortality. On the other hand, there are researches that reported a beneficial effect of antihypertensive medication by decreasing mortality in the cancer patients. One should be aware of the discrepancy of investigated antihypertensives in these researches and heterogeneity of included patients - different age, cancer type, comorbidities, demographic characteristics, and anti-cancer therapy. This comprehensive review article aimed to summarize the current knowledge regarding the relationship between antihypertensive medications and cancer.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Beta-blocker; Calcium-channel blockers; Cancer; Diuretics; Renin-angiotensin inhibitors; Thiazides

Mesh:

Substances:

Year:  2019        PMID: 30682424     DOI: 10.1016/j.phrs.2019.01.037

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  3 in total

1.  Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong.

Authors:  Jinhui Li; Amy S M Lam; Sarah T Y Yau; Karen K L Yiu; Kelvin K F Tsoi
Journal:  BMC Cancer       Date:  2021-11-11       Impact factor: 4.430

2.  Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Cancer: A Population-Based Cohort Study Using a Common Data Model.

Authors:  Seung-Hwa Lee; Jungchan Park; Rae Woong Park; Seo Jeong Shin; Jinseob Kim; Ji Dong Sung; Dae Jung Kim; Kwangmo Yang
Journal:  Diagnostics (Basel)       Date:  2022-01-21

3.  Prognostic impact of angiotensin-converting enzyme inhibitors and angiotensin receptors blockers in esophageal or gastric cancer patients with hypertension - a real-world study.

Authors:  Kun-Pin Hsieh; Yi-Hsin Yang; Po-Chih Li; Ru-Yu Huang; Yu-Chien Yang
Journal:  BMC Cancer       Date:  2022-04-20       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.